Actimis Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Actimis Pharmaceuticals Inc. spun out from the research division of Bayer Healthcare AG with rights to five programs that represent a significant portion of the total Bayer small-molecule therapeutics portfolio for respiratory diseases. In the first quarter of 2006, the company hopes to move its first compound, a novel and potential breakthrough asthma treatment, into human trials.
You may also be interested in...
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
Polaris Stays Disciplined For Breakthroughs: An Interview With Alan Crane
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.